Clinical and preclinical data suggest that anti-PTX3 antibodies have anti-inflammatory and immunomodulatory effects in SLE [10–15], and ANCA-associated vasculitis (AAV) [16, 17]. Here, PTX3 is linked to systemic lupus erythematosus.